# Quantile Normalization for RNA-seq and Microarray Integration

Quantile normalization forces the full intensity distribution of every sample to be identical, which makes it a natural fit for microarrays and a risky, conditional fit for RNA-seq. The one-sentence rule of thumb is this: use quantile normalization when your platform differences are mostly technical and your biology is mostly balanced across samples, and switch to log2 plus z-score standardization or a joint cross-platform pipeline when the platforms themselves carry the signal you care about.

This article walks through what quantile normalization actually computes, why combining RNA-seq and microarray data is harder than either platform alone, the main options for integration, the pros and cons of each, worked scenarios, and the mistakes that cause most failed meta-analysis projects. If you are troubleshooting a cross-platform analysis that keeps failing, the sections on options, scenarios, and common mistakes are written for you.

## What Quantile Normalization Actually Does

![Rank means of 105, 200 and 700 worked out from two samples of three genes and reassigned back to each gene position.](/article-images/illustrations/quantile-normalization-rna-seq-microarray-integration-rank-mean-example.webp)

Quantile normalization is a transformation that makes the empirical distribution of values identical across all samples in a dataset. It was popularized by Bolstad and colleagues for Affymetrix oligonucleotide arrays and remains the default in most microarray [preprocessing](/blog/data-analysis/what-is-data-preprocessing) pipelines, including the Robust Multi-array Average (RMA) workflow.

The algorithm has four steps, applied column-wise, where each column is one sample:

1. Sort the values within each sample from lowest to highest.
2. Compute the mean of each rank across all samples. Rank 1 mean, rank 2 mean, and so on, across every column.
3. Build a matrix where column j contains those rank means in sorted order.
4. Unsort each column back into its original row order, replacing each original value with the mean of the rank it occupied.

A tiny worked example makes this concrete. Suppose you have two samples with three genes:

| Gene | Sample A | Sample B |
|--|--|--|
| Gene1 | 10 | 200 |
| Gene2 | 100 | 300 |
| Gene3 | 1000 | 400 |

Sorted, Sample A is 10, 100, 1000 and Sample B is 200, 300, 400. The rank means are (10+200)/2 = 105, (100+300)/2 = 200, and (1000+400)/2 = 700. After unsorting, Sample A becomes 105, 200, 700 for Gene1, Gene2, Gene3, and Sample B becomes 200, 700, 105 for Gene1, Gene2, Gene3. Both samples now have exactly the same distribution of values, but the ordering of genes within each sample is preserved. Gene3 was the highest in Sample A and remains the highest value assigned to its position, while Gene1 keeps its low rank in both.

Two properties follow directly from this mechanism, and both matter enormously in cross-platform work:

- The transformation preserves the rank order of genes within each sample. Relative orderings survive, absolute expression levels do not.
- The transformation assumes that only a minority of genes differ between samples and that the overall distribution of expression should be the same in every sample. When most genes in one condition genuinely shift upward, quantile normalization removes that shift.

That second property is the root of most trouble when people apply quantile normalization to RNA-seq or to cross-platform datasets with unbalanced biology.

## Why RNA-seq and Microarray Integration Is Hard

Microarrays measure hybridization intensity of fluorescently labeled cDNA or cRNA bound to fixed probes. RNA-seq measures the number of sequencing reads aligned to each transcript. The two technologies produce numbers on fundamentally different scales with different error structures.

Consider the specific differences that break naive merging:

**Measurement scale and dynamic range.** Microarray intensities are continuous values with a floor of background noise, typically spanning two to four orders of magnitude after background correction. RNA-seq counts are integers that can span six or more orders of magnitude, from zero to hundreds of thousands of counts for a single highly expressed transcript in a deep library. Count data follow a negative binomial-like distribution, not a normal one, which is why [RNA-seq differential expression](/knowledge/bioinformatics/rna-seq-differential-expression-deseq2-edger) tools such as DESeq2 and edgeR model counts directly rather than log-transforming raw counts first.

**Gene-level versus transcript-level resolution.** Microarray probes interrogate specific sequence regions, often 3' biased on older platforms such as Affymetrix HG-U133 Plus 2.0. RNA-seq reads cover the whole transcript. A gene with alternative 3' ends can show different microarray and RNA-seq values for purely technical reasons.

**Probe-to-gene mapping.** Multiple probes can map one gene on a microarray, and read mapping ambiguity hits multi-gene families in RNA-seq. Any cross-platform method needs an explicit, documented mapping decision, and that decision changes results.

**Zeros and negatives.** RNA-seq genes with zero reads in a sample have no defined log value. Microarray background correction can produce small negative corrected intensities. Both require explicit handling rules before any joint normalization step.

**Platform-specific bias.** The same gene measured on both platforms shows systematic differences caused by probe sequence, GC content, transcript isoform coverage, and library preparation chemistry. These biases do not vanish with per-platform normalization.

The practical consequence is that you cannot simply concatenate a microarray expression matrix and a gene count matrix and run one normalization function across the combined columns. You need a pipeline that addresses scale, mapping, and distribution together.

## Your Integration Options, Side by Side

Here is the decision table for the realistic options. Each row is expanded in its own section below.

| Option | What it does | Best for | Main risk | Typical tools |
|--|--|--|--|--|
| Quantile normalization applied across platforms | Forces identical value distributions in all samples from both platforms | Datasets with balanced biology, similar platform coverage, and a shared log-scale expression matrix | Erases genuine global expression differences and between-platform signal needed for prediction | limma `normalizeBetweenArrays`, `preprocessCore` |
| Log2 plus z-score standardization | Log-transforms each platform to a common scale, then standardizes each gene to mean zero, variance one | Predictive modeling and machine learning on cross-platform data | Loses absolute expression information, can amplify noise in low-count genes | Base R, scikit-learn, applied in UCResponNet-X style frameworks [1] |
| Joint normalization with unified interval matching | Maps reads and probes to a common custom target definition, then binds, normalizes, and summarizes together | Projects mixing NGS, microarray, SAGE, or MPSS data with flexible reference definitions | Requires pipeline setup and custom reference curation | AnyExpress [2] |
| Per-platform normalization followed by batch correction | Normalizes each platform correctly on its own, then applies ComBat or linear models to remove platform effects | Large multi-cohort datasets with clear batch structure | Can remove real biological signal if batch and phenotype are confounded | sva `ComBat`, limma `removeBatchEffect` |
| Rank-based or rank-product integration | Converts each platform to gene ranks or percentile ranks, then combines | Robust signature overlap analysis when absolute scale is irrelevant | Discards magnitude information, weaker for fold-change estimation | RankProd, simple rank aggregation |
| Separate per-platform analysis followed by meta-analysis | Runs differential expression independently per platform, then combines statistics | Answering "which genes are consistently differentially expressed" rather than building a merged matrix | Cannot train a single model on merged features, requires gene-level effect direction agreement | metaRNASeq style workflows, random-effects models |

The single most common question in this space is whether quantile normalization alone is the best choice for RNA-seq and microarray integration. The honest answer, supported by direct comparison studies, is that it is often not. In a framework built to predict infliximab response in ulcerative colitis from three microarray cohorts tested on an external RNA-seq dataset, z-score and log2 normalization substantially outperformed quantile normalization at preserving predictive signal across platforms, reaching a mean cross-validation AUC of 0.824 and an external RNA-seq test AUC of 0.821 [1]. Quantile normalization was evaluated in that same unified protocol and underperformed both alternatives. That result does not make quantile normalization useless. It makes it the wrong default for machine learning on cross-platform data, which is exactly the use case most people have.

## Option 1: Quantile Normalization Applied Across Platforms

### How it works in a microarray context

For a single microarray platform, quantile normalization is almost always correct. Affymetrix arrays from the same batch share a probe set, a scanning protocol, and an expected intensity distribution, so forcing identical distributions removes technical variation without distorting biology. The standard RMA pipeline applies background correction, quantile normalization across all arrays, and median polish summarization, and this is implemented in packages such as `affy` and `oligo`.

A typical R call looks like this:

```r
library(oligo)
raw <- read.celfiles(list.celfiles("cel_dir/", full.names=TRUE))
background_corrected <- backgroundCorrect(raw, method="rma")
normalized <- normalize(background_corrected, method="quantile")
```

For expression arrays from two microarray platforms, quantile normalization across the merged matrix after probe-to-gene collapsing is a defensible starting point, provided both platforms were log2 transformed first.

### Applying it to RNA-seq, and where it breaks

Two distinct situations exist for RNA-seq.

**Situation one, RNA-seq already converted to a microarray-like scale.** If you have RNA-seq data summarized to gene-level log2 CPM (counts per million) or TPM (transcripts per million), the values are continuous, positive, roughly log-normal, and distributed over a range comparable to log microarray intensities. At that point, quantile normalization across all samples from both platforms can work, and it is what several published cross-platform studies do. The precondition is that per-gene values on the two platforms measure the same underlying quantity and that biology is balanced across samples.

**Situation two, raw counts.** Applying quantile normalization directly to a raw integer count matrix is generally a mistake. Counts are sparse, zero-inflated, and library-size dependent. Quantile normalizing raw counts destroys the count-scale statistical properties that DESeq2 and edgeR rely on, produces impossible fractional counts, and can create negative or nonsensical values in the lower quantiles. If a reviewer sees raw counts quantile normalized, that alone flags the analysis.

A third, subtler failure mode deserves its own paragraph. Quantile normalization assumes that within any sample, most genes are not differentially expressed relative to the dataset average. In datasets where an entire condition shifts expression globally, for example a treatment that broadly suppresses transcription, quantile normalization forces the shifted condition back toward the reference distribution and can erase the very signal you are hunting. This artifact is well documented in single-platform analysis and it gets worse across platforms, because platform effects and biology are entangled in the same distribution shift.

### Pros and cons for cross-platform integration

**Pros:**

- Removes distribution-level platform effects, which are among the largest artifacts in merged data.
- Preserves within-sample gene rank order, which is what most ranking-based downstream analyses need.
- Simple, fast, deterministic, and available in every microarray package.
- Well understood by reviewers, so it is easy to defend when applied to comparable, log-scale, gene-level matrices.

**Cons:**

- Assumes balanced biology, which cross-platform studies frequently violate.
- Destroys between-sample absolute expression differences, which predictive models often use.
- Direct evidence from a head-to-head comparison shows quantile normalization underperforms z-score and log2 standardization for cross-platform predictive modeling, where the platform difference is exactly the transfer target [1].
- Not valid on raw RNA-seq counts.
- Offers no solution to probe-to-gene mapping differences, which quantile normalization never addresses.

## Option 2: Log2 Transformation Plus Z-Score Standardization

Z-score standardization converts each gene's values into standard deviation units. For gene g across all samples from both platforms, you compute the mean m and standard deviation s, then replace each value x with (x - m) / s. After this step, every gene has mean zero and standard deviation one across the merged dataset, so the contribution of each gene to a distance metric or classifier is scale independent.

The typical pipeline is:

1. Normalize each platform correctly on its own. Microarrays through RMA or a similar workflow, RNA-seq through TMM (trimmed mean of M values) or DESeq2 size factors, then log2 CPM with a small offset.
2. Collapse microarray probes to genes, keeping the same gene identifier system on both sides, usually Ensembl gene IDs or HGNC symbols.
3. Log2 transform both matrices if not already on the log scale. Add a small offset, commonly 1, before taking logs of CPM values to avoid undefined values at zero counts.
4. Intersect genes present on both platforms.
5. Apply z-score standardization per gene across the merged matrix.
6. Optionally apply batch correction afterward.

The rationale for why this beats quantile normalization in predictive settings is mechanical. Quantile normalization compresses the top and bottom of each sample's distribution toward shared rank means, discarding magnitude. A classifier trying to distinguish responders from non-responders often uses expression magnitude patterns. Z-scoring keeps each gene's relative magnitudes intact while equalizing gene-wise scale contributions. The ulcerative colitis drug response study compared these strategies systematically under one cross-validation protocol and found z-score and log2 normalization superior to quantile normalization for cross-platform [generalizability](/blog/data-analysis/generalizability-in-research) of the models [1].

The costs are real. You lose absolute expression, so you cannot say "gene X is expressed at Y copies per cell" after z-scoring. Genes with very low variance in the merged set get inflated standardized values from small measurement noise, so filtering low-variance or low-expression genes before z-scoring is standard practice. And z-scoring per gene across the merged matrix assumes the gene means and variances are comparable across platforms, which is only approximately true. When platform differences are large, batch correction applied after z-scoring usually helps.

## Option 3: Joint Pipelines With Unified Interval Matching

The options above all start after the hard problem is solved, which is getting microarray probes and RNA-seq reads to represent the same genes. A different class of tool attacks the problem upstream by defining a common target space and mapping both data types into it before normalization.

AnyExpress is the clearest published example. It was built specifically because cross-platform [gene expression](/blog/guides/gene-expression) analysis requires multiple interlocking steps, existing tools handled a single platform each, and reference information such as genome builds and transcriptome databases is frequently outdated or erroneous, which produces incorrect and misleading output [2]. AnyExpress uses a fast interval-matching algorithm to combine data from next-generation sequencing, microarray, SAGE, and MPSS technologies. Users can define custom target transcriptome references for probe and read mapping in any species and set criteria to remove undesirable probes and reads. Binding, normalization, and summarization then operate in a single scalable framework [2].

In the published case study, AnyExpress processed published Affymetrix microarray and Illumina NGS RNA-seq data from human kidney and liver, achieving a mean within-platform correlation coefficient of 0.98 for within-platform samples in kidney and liver [2]. The abstract also reports high cross-platform correlation after integration, which is the number that matters for merged analyses.

The interval-matching idea is worth understanding even if you never run the tool. Instead of mapping each platform's measurement to a gene symbol and hoping the annotations agree, you define intervals, typically exons or exonic regions from a chosen transcriptome build, and assign every microarray probe and every sequencing read to the intervals it overlaps. Measurements from both platforms then describe the same interval set, which removes an entire category of annotation mismatch before any normalization happens. Filtering rules, such as dropping probes with SNPs in the target region or reads with multi-mapping ambiguity, are applied with the same explicit logic on both sides [2].

The trade-off is setup cost. You curate or accept a reference interval definition, and any change in reference version means remapping. For a one-off integration of two well-annotated human datasets, the lighter options may suffice. For recurring integrations, non-model species, or mixed technology panels that include SAGE or MPSS alongside modern platforms, a unified pipeline earns its setup cost.

## Option 4: Per-Platform Normalization, Then Batch Correction

This is the strategy most statisticians recommend as the default starting point, and it deserves careful description because it is frequently confused with quantile normalization.

The logic is that each platform should be normalized correctly on its own first, using the methods designed for it, and that platform differences should then be modeled and removed as a batch effect.

1. Microarrays: RMA or normexp background correction, quantile normalization within the microarray platform, log2 summarization.
2. RNA-seq: library size correction with TMM or DESeq2 size factors, then log2 CPM or a variance-stabilizing transformation such as limma-voom, which estimates per-observation weights from the mean-variance relationship of the counts.
3. Merge on a common gene identifier, intersect genes, log2 transform both to comparable ranges.
4. Fit a linear model containing your biological condition of interest plus a platform indicator variable, and remove the platform term. The `limma` function `removeBatchEffect` does this for visualization and downstream clustering, while keeping the design in the model if you continue with differential expression. The `ComBat` function from the `sva` package applies an empirical Bayes adjustment of location and scale parameters.

The key conceptual point is that batch correction after correct per-platform normalization usually dominates raw cross-platform quantile normalization, because ComBat and removeBatchEffect estimate the platform effect per gene, while quantile normalization applies a single global distributional correction that cannot know which genes are systematically biased on one platform.

The key practical risk is confounding. If every microarray sample is a control and every RNA-seq sample is a treated tumor, platform and biology are perfectly confounded, and no method, not ComBat, not quantile normalization, not anything, can separate them. Before choosing this option, check that both platforms contain samples from more than one biological condition.

## How to Choose: Three Worked Scenarios

**Scenario one, you want to merge 40 Affymetrix arrays with 30 RNA-seq samples to find genes consistently associated with disease status, and both conditions appear on both platforms.** Start with option four. Normalize each platform properly, collapse probes to genes, intersect, log2, then ComBat or removeBatchEffect with a design that includes disease status and platform. Check the result with a PCA colored by platform before correction and after. If platform effects dominate after correction, add option three's interval-matching logic by remapping probes with a current annotation, since outdated probe annotations are a known source of incorrect results [2]. Quantile normalization across the merged matrix is a reasonable secondary comparison, but do not make it your only analysis.

**Scenario two, you are training a machine learning classifier on microarray cohorts and testing it on an independent RNA-seq cohort.** Start with option two. Log2 transform and z-score each gene across the merged training matrix, apply the same gene-wise mean and standard deviation parameters to the test cohort, and evaluate transfer. The published head-to-head evidence supports z-score and log2 standardization over quantile normalization for exactly this purpose, with cross-validation AUC up to 0.824 and external RNA-seq AUC of 0.821 in the referenced framework [1]. Add biologically informed feature selection before the classifier, since platform differences concentrate in a subset of genes and feature selection reduces their influence.

**Scenario three, you are integrating RNA-seq with legacy SAGE or MPSS data, or working in a non-model organism where gene annotations differ between your platforms.** Start with option three. A joint pipeline with custom interval matching is designed for exactly this heterogeneity, and the ability to define your own target transcriptome reference and filtering criteria is the reason such tools exist [2]. Standard gene-symbol merging will silently lose or corrupt a large fraction of features in this setting.

## Common Mistakes and Limitations

Most failed cross-platform projects fail for a short list of reasons. These are the ones seen repeatedly in review and replication.

**Quantile normalizing raw RNA-seq counts.** This destroys the count-based error model and produces undefined or meaningless values. RNA-seq counts need size-factor or CPM-style normalization first, then log transformation, before any cross-platform distribution matching is even discussable.

**Treating quantile normalization and batch correction as interchangeable.** They do different things. Quantile normalization equalizes value distributions, which is a global, non-gene-specific operation. ComBat and removeBatchEffect estimate and remove per-gene location and scale shifts associated with a known covariate. Applying one when you need the other is among the most common bioinformatics troubleshooting calls in merged datasets.

**Merging on out-of-date or inconsistent gene identifiers.** Reference databases are periodically corrected and versioned, and tools coupled tightly to stale references produce incorrect or misleading results, which is one of the explicit motivations for pipelines with user-defined references [2]. Always record the annotation version and gene identifier system. A gene symbol like "ABC1" has been reassigned historically in ways that silently mismap expression values.

**Ignoring the zero and negative value problem.** Log2 of zero is undefined and background-corrected microarray values can be negative. Every pipeline needs an explicit rule, such as a log2(CPM + 1) offset or a floor on corrected intensities, and that rule should be stated in your methods.

**Applying quantile normalization when biology is globally shifted.** If one condition broadly changes transcription, the equal-distribution assumption fails and real signal gets removed. Inspect relative log expression (RLE) plots and density plots before and after. If the density curves of untreated and treated samples differed strongly before normalization and become identical after, with your positive control genes flattened, you have normalized away biology.

**Not checking whether the RNA-seq error structure survives.** Common RNA-seq error modes include library size imbalance, gene length bias in TPM comparisons across conditions, batch effects from library preparation date, and multi-mapping ambiguity in gene families. Cross-platform integration inherits all of these on top of platform effects, and no single normalization step fixes them. A typical RNA-seq error that surfaces only after merging is that a gene with many paralogous reads shows systematically inflated RNA-seq values relative to its microarray measurement, which quantile normalization cannot correct because it is gene-specific, not distributional.

**Perfect confounding of platform with condition.** As noted above, no method recovers information that was never measured independently. Design your dataset, or at minimum acknowledge this limitation explicitly in your results.

**Skipping the sanity checks.** A merged dataset should pass three quick tests before any expensive downstream analysis. Correlation of the same gene across platforms should be clearly positive for most genes after normalization. PCA should show samples grouping by biology, not by platform, after correction. Known housekeeping genes should show stable relative expression. If any of these fail, stop and debug rather than proceeding.

**Expecting normalization to fix design problems.** Normalization corrects systematic technical variation between samples measured under comparable conditions. It cannot compensate for missing replicates, unbalanced groups, or samples processed with different tissue handling protocols. If the study design is weak, no normalization choice rescues it.

One more limitation applies to every option here. Cross-platform integration always trades something away, whether absolute expression, isoform resolution, or [statistical power](/blog/guides/statistical-power-what-it-is-and-why-it-matters-in-research), and the right choice depends on which downstream analysis you intend to run. Define the downstream analysis first, then choose the normalization, not the reverse.

## A Practical QC Checklist for Merged Datasets

![Three panels listing platform-separated PCA, per-gene cross-platform correlation and relative log expression as sanity checks for a merged dataset.](/article-images/illustrations/quantile-normalization-rna-seq-microarray-integration-qc-checks.webp)

Run these checks in order. Each one catches a specific failure mode from the list above.

1. **Per-platform QC first.** Confirm each platform's data looks clean on its own before merging. Microarray density plots should overlap, RNA-seq library sizes should be within a reasonable range of each other, and PCA within each platform should reflect biology, not run date.
2. **Gene intersection report.** Record how many genes survive identifier mapping and intersection. If you lose more than roughly a quarter of detected features, suspect annotation version problems before suspecting biology.
3. **Before-and-after PCA.** Color samples by platform. If platform separates samples after correction the way it did before, your correction failed or is confounded with biology.
4. **RLE plots.** After normalization, the median relative log expression per sample should hover near zero with tight spread. Drifting medians indicate residual normalization failure.
5. **Cross-platform gene-wise correlation.** Compute Pearson correlation per gene between platform-matched values. A strong mode of positive correlations indicates successful integration, a flat or negative mode indicates mapping or scale problems.
6. **Control genes.** Housekeeping genes should be stable across samples and platforms. If a housekeeping gene shows a large platform effect after correction, treat its measurement with suspicion and check its probe annotation.

## Frequently Asked Questions

### Can I apply quantile normalization directly to raw RNA-seq counts?

No. Raw counts are sparse, library-size dependent, and modeled with count distributions that quantile normalization destroys. Convert counts to log2 CPM or a similar log-scale measure with proper size-factor correction first, and only then consider cross-platform distribution matching.

### Is quantile normalization the best method for RNA-seq and microarray integration?

Often no. For predictive modeling across platforms, head-to-head comparisons show z-score and log2 standardization outperform quantile normalization at preserving signal across the platform gap. Quantile normalization remains appropriate for within-platform microarray preprocessing and as one option among several for merged log-scale matrices.

### What is the difference between quantile normalization and batch correction?

Quantile normalization forces all samples to share one value distribution and is not gene-specific. Batch correction methods such as ComBat estimate per-gene location and scale shifts linked to a known covariate, such as platform, and remove them while preserving other design factors. Use both in sequence when appropriate, not one in place of the other.

### Should I quantile normalize before or after log2 transformation?

Standard microarray practice applies quantile normalization to background-corrected intensities and then log2 transforms during summarization, which is how the RMA pipeline orders the steps. For cross-platform work, log2 transform each platform on its own scale first, then decide whether an additional cross-platform quantile step is justified by balanced biology.

### Which tools support cross-platform normalization workflows?

For per-platform normalization plus batch correction, the R packages `limma`, `oligo`, `edgeR`, and `sva` cover most needs. For joint binding, normalization, and summarization across sequencing and microarray technologies with custom reference definitions, AnyExpress implements a fast interval-matching algorithm supporting NGS, microarray, SAGE, and MPSS data.

### How do I know whether my cross-platform normalization worked?

Check three things. After correction, PCA colored by platform should no longer separate samples by platform, per-gene cross-platform correlations should show a clear positive mode, and relative log expression plots should center near zero for every sample. If any check fails, revisit mapping, confounding, and choice of normalization before proceeding.

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "Can I apply quantile normalization directly to raw RNA-seq counts?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No. Raw counts are sparse, library-size dependent, and modeled with count distributions that quantile normalization destroys. Convert counts to log2 CPM or a similar log-scale measure with proper size-factor correction first, and only then consider cross-platform distribution matching."
      }
    },
    {
      "@type": "Question",
      "name": "Is quantile normalization the best method for RNA-seq and microarray integration?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Often no. For predictive modeling across platforms, head-to-head comparisons show z-score and log2 standardization outperform quantile normalization at preserving signal across the platform gap. Quantile normalization remains appropriate for within-platform microarray preprocessing and as one option among several for merged log-scale matrices."
      }
    },
    {
      "@type": "Question",
      "name": "What is the difference between quantile normalization and batch correction?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Quantile normalization forces all samples to share one value distribution and is not gene-specific. Batch correction methods such as ComBat estimate per-gene location and scale shifts linked to a known covariate, such as platform, and remove them while preserving other design factors. Use both in sequence when appropriate, not one in place of the other."
      }
    },
    {
      "@type": "Question",
      "name": "Should I quantile normalize before or after log2 transformation?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Standard microarray practice applies quantile normalization to background-corrected intensities and then log2 transforms during summarization, which is how the RMA pipeline orders the steps. For cross-platform work, log2 transform each platform on its own scale first, then decide whether an additional cross-platform quantile step is justified by balanced biology."
      }
    },
    {
      "@type": "Question",
      "name": "Which tools support cross-platform normalization workflows?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "For per-platform normalization plus batch correction, the R packages limma, oligo, edgeR, and sva cover most needs. For joint binding, normalization, and summarization across sequencing and microarray technologies with custom reference definitions, AnyExpress implements a fast interval-matching algorithm supporting NGS, microarray, SAGE, and MPSS data."
      }
    },
    {
      "@type": "Question",
      "name": "How do I know whether my cross-platform normalization worked?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Check three things. After correction, PCA colored by platform should no longer separate samples by platform, per-gene cross-platform correlations should show a clear positive mode, and relative log expression plots should center near zero for every sample. If any check fails, revisit mapping, confounding, and choice of normalization before proceeding."
      }
    }
  ]
}
</script>


## Sources

1. [UCResponNet-X: cross-platform multi-dataset gene expression for predictive modeling of drug response in ulcerative colitis.](https://pubmed.ncbi.nlm.nih.gov/42717746/)
2. [AnyExpress: integrated toolkit for analysis of cross-platform gene expression data using a fast interval matching algorithm.](https://pubmed.ncbi.nlm.nih.gov/21410990/)